Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date.
Sam M PearsonNoppadol KietsirirojeRamzi A AjjanPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2019)
In recent years, newer drug classes for the treatment of type 2 diabetes mellitus have been released with significant effects on glucose lowering and weight reduction. One of the most promising classes in achieving these goals has been the glucagon-like peptide (GLP)-1 agonists. However, a difficulty with the use of these agents is the need for subcutaneous injections, which can be inconvenient to individuals living with type 2 diabetes. More recently, a GLP-1 agonist has been developed, semaglutide, that can be administered orally which has at least similar effects to the subcutaneous preparation from which this compound is derived. In this review article, we discuss the glycemic and cardiovascular effects of the GLP-1 agonists with special emphasis on oral semaglutide and the potential role of this therapy in individuals with type 2 diabetes.
Keyphrases
- type diabetes
- body mass index
- physical activity
- weight loss
- emergency department
- stem cells
- blood glucose
- combination therapy
- weight gain
- metabolic syndrome
- bone marrow
- adipose tissue
- public health
- blood pressure
- mass spectrometry
- skeletal muscle
- glycemic control
- adverse drug
- cell therapy
- high resolution
- climate change
- simultaneous determination